<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>前免疫</title><link/>https://pubmed.ncbi.nlm.nih.gov/?sort = date&amp;term=101560960%20%20%5BNLMID%5D&amp;v=2.18.0.post9+E462414&amp;fc=无＆utm_campaign =期刊＆utm_medium = rss＆utm_content = 101560960＆ff = 20250414161247＆utm_source = chrome<description>前免疫：PubMed的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/?sort=date&amp;term=101560960%20%5BNLMID%5D&amp;v=2.18.0.post9+e462414&amp;fc=None&amp;utm_campaign=journals&amp;utm_medium=rss&amp;utm_content=101560960&amp;ff=20250414161247&amp;utm_source=Chrome" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS提要（2.18.0.post9+E462414）</generator><language> en</language><lastbuilddate> 2025年4月14日星期一20:12:48 +0000</lastbuilddate><pubDate> Mon, 14 Apr 2025 06:00:00 -0400</pubDate><ttl> 120</ttl><item><title>病例报告：抗PD-1抗体CAMRelizumab诱导的皮肤狼疮红斑狼疮与化学疗法结合</title><link/>https://pubmed.ncbi.nlm.nih.gov/40226630/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250414161247＆v = 2.18.0.post9+e462414<description>结论：CAMRelizumab治疗可能与阳光暴露的皮肤区域中亚急性皮肤红斑狼疮的出现有关，这可以通过局部和全身性糖皮质激素和羟基氯喹迅速缓解。建议对诊断和治疗进行早期抗体测试和皮肤活检。与经典的与药物相关的SCLE不同，患者可能会出现多种自身免疫性疾病，并且在使用免疫检查点抑制剂以进行后续时应谨慎行事... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月28日； 16：1539373。 doi：10.3389/fimmu.2025.1539373。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">免疫检查点抑制剂（ICI）的使用会导致与免疫相关的不良事件（IRAE），其中皮肤IRAE很常见，影响多达50％的ICI治疗患者。尽管在接受抗编程性死亡-1（抗PD-1）免疫疗法的患者中，仅报告了几例亚急性皮肤红斑狼疮（SCLE）（SCLE），但重要的是识别ICI诱导的SCLE很重要，因为即使在治疗后可能会导致延迟和/或延长皮肤反应。迄今为止，尚无与CAMRelizumab治疗相关的皮肤狼疮病例。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">病例报告：我们报告了一例患有晚期非小细胞肺癌（NSCLC）患者的病例，该患者在一种抗PD-1抗体CAMRELIZUMAB与化学疗法结合后，在阳光暴露的皮肤上逐渐形成红斑皮疹。皮疹最初被认为是湿疹，但在症状治疗后没有改善。第三次治疗后，皮疹继续恶化，瘙痒是难以忍受的。抗体测试后，发现患者具有阳性抗SS-A/RO抗体，组织学变化与亚急性皮肤红斑狼疮一致。 SCLE由局部和全身性糖皮质激素，羟氯喹以及抗PD-1疗法的中断控制。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：CAMRelizumab治疗可能与阳光暴露的皮肤区域中亚急性皮肤红斑狼疮的出现有关，这可以通过局部和全身性糖皮质激素和羟基氯喹迅速缓解。建议对诊断和治疗进行早期抗体测试和皮肤活检。与经典的与药物相关的SCLE不同，患者可能患有多种自身免疫性疾病，在使用免疫检查点抑制剂进行后续治疗时，应谨慎行事。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40226630/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250414161247&v=2.18.0.post9+e462414">40226630</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11985835/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250414161247&v=2.18.0.post9+e462414">PMC11985835</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1539373>10.3389/fimmu.2025.1539373</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40226630</guid><pubDate> Mon, 14 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Hejing Bao</dc:creator><dc:creator>贾安尼张</dc:creator><dc:creator>xi luo</dc:creator><dc:creator>小歌</dc:creator><dc:creator>胡安·李</dc:creator><dc:creator>南毛</dc:creator><dc:creator>方陈</dc:creator><dc:creator>Hehong Bao</dc:creator><dc:creator> Jiazhu Hu</dc:creator><dc:creator>小关</dc:creator><dc:creator>硕士</dc:creator><dc:creator>唇lin</dc:creator><dc:date> 2025-04-14</dc:date><dc:source>免疫学领域</dc:source><dc:title>病例报告：抗PD-1抗体CAMRelizumab诱导的皮肤狼疮红斑狼疮与化学疗法结合</dc:title><dc:identifier>PMID：40226630</dc:identifier><dc:identifier> PMC：PMC11985835</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1539373</dc:identifier></item><item><title>先天性免疫错误的基因组和转录组测序：可行的多摩变诊断方法</title><link/>https://pubmed.ncbi.nlm.nih.gov/40226629/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250414161247＆v = 2.18.0.post9+e462414<description>天生的免疫力错误（IEI）是一组涉及500多个基因的稀有稀有先天疾病，尽管下一代测序进步，但仍面临诊断挑战。准确的分子诊断对于个性化治疗至关重要。这项研究旨在评估基因组和转录组测序在改善先天免疫错误诊断产率中的互补作用。 37个怀疑IEI病例的队列主要由主要由抗体缺乏症（PAD）组成。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月28日； 16：1510365。 doi：10.3389/fimmu.2025.1510365。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">天生的免疫力错误（IEI）是一组涉及500多个基因的稀有稀有先天疾病，尽管下一代测序进步，但仍面临诊断挑战。准确的分子诊断对于个性化治疗至关重要。这项研究旨在评估基因组和转录组测序在改善先天免疫错误诊断产率中的互补作用。 37个怀疑的IEI病例的队列主要由主要由抗体缺乏症（PAD）（27/37）组成，进行了基因组和转录组测序。我们使用阳性对照验证了转录组测序分析，并显示了当前方法的局限性。在37例IEI病例中，在14％（5/37）中鉴定出遗传病因。基因组和转录组测序促使三种最初诊断的常见可变免疫缺陷（CVID）/PAD病例的诊断变化，包括显示与Ras相关的自身免疫性白细胞增生性疾病，作为一种新型的CVID模拟障碍。鉴定的致病变异的光谱包括<i>STAT1</i> ， <i>ADA2</i> ， <i>SH2D1A</i> ， <i>NRA</i>和<i>NR2F1</i> 。表征了<i>SH2D1A</i>中的复杂结构变体，证明了转录组测序在阐明基因组发现中的重要性。尽管基因组和转录组测序提供了关键的见解，并允许至少14％的患者提供正确的诊断，但外显子组测序的诊断产量的总体提高是有限的。转录组测序在变异效应解释中被证明有效。我们的发现强调了原发性免疫缺陷遗传学的不断发展的景观，需要对新型基因和非典型表型进行持续的探索。基因组和转录组测序的整合具有前景，但需要进一步完善以提高诊断产量。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40226629/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250414161247&v=2.18.0.post9+e462414">40226629</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11986850/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250414161247&v=2.18.0.post9+e462414">PMC11986850</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1510365>10.3389/fimmu.2025.1510365</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40226629</guid><pubDate> Mon, 14 Apr 2025 06:00:00 -0400</pubDate><dc:creator>大麻Rozevska</dc:creator><dc:creator>卡特里娜·戴拉·尼伯加·维格特（Katrina Daila Neiburga-Vigante）</dc:creator><dc:creator> Inga Nartisa</dc:creator><dc:creator> Zane Lucane</dc:creator><dc:creator> Lota Ozola</dc:creator><dc:creator> Livija Bardina</dc:creator><dc:creator> Inta Jaunalksne</dc:creator><dc:creator> Natalija Gerula</dc:creator><dc:creator>佩特拉·克里克（Petra Krike）</dc:creator><dc:creator> Gita Taurina</dc:creator><dc:creator> Ieva Nokalna-Spale</dc:creator><dc:creator> Ieva Micule</dc:creator><dc:creator> Baiba Vilne</dc:creator><dc:creator> Kai Kisand</dc:creator><dc:creator> Sander Pajusalu</dc:creator><dc:creator> Linda Gailite</dc:creator><dc:creator> dmitrijs腐烂</dc:creator><dc:creator>Natalja Kurjane</dc:creator><dc:date> 2025-04-14</dc:date><dc:source>免疫学领域</dc:source><dc:title>先天性免疫错误的基因组和转录组测序：可行的多摩变诊断方法</dc:title><dc:identifier>PMID：40226629</dc:identifier><dc:identifier> PMC：PMC11986850</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1510365</dc:identifier></item><item><title>胸腺居民B细胞的早期生活平衡分化为记忆B细胞</title><link/>https://pubmed.ncbi.nlm.nih.gov/40226628/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250414161247＆v = 2.18.0.post9+e462414<description>胸腺中包含各种抗原呈递细胞，包括B细胞，即使在稳态条件下也被激活，这表明持续的局部刺激。在这项研究中，我们鉴定了胸腺中的类切换的记忆B细胞。这些细胞中的一些细胞将其免疫球蛋白转换为IgG2b和IgA，并表达典型的内存标记CD73和PD-L2。胸腺中的记忆B细胞分化始于新生儿小鼠，在其他外周中的类切换B细胞的出现之前... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月28日； 16：1567788。 doi：10.3389/fimmu.2025.1567788。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">胸腺中包含各种抗原呈递细胞，包括B细胞，即使在稳态条件下也被激活，这表明持续的局部刺激。在这项研究中，我们鉴定了胸腺中的类切换的记忆B细胞。这些细胞中的一些细胞将其免疫球蛋白转换为IgG2b和IgA，并表达典型的内存标记CD73和PD-L2。胸腺中的记忆B细胞分化开始于新生儿小鼠，在其他外周淋巴器官中类切换的B细胞的出现之前。值得注意的是，暴露于环境抗原不会影响其分化。另外，与CD4 <sup>+</sup>阳性胸腺细胞的同源相互作用对于胸腺中记忆B细胞的发展至关重要。我们的发现表明，胸腺通过稳态过程支持记忆B细胞的局部分化，与外国抗原刺激无关，并由与发育中的T细胞的相互作用驱动。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40226628/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250414161247&v=2.18.0.post9+e462414">40226628</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11985456/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250414161247&v=2.18.0.post9+e462414">PMC11985456</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1567788>10.3389/fimmu.2025.1567788</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40226628</guid><pubDate> Mon, 14 Apr 2025 06:00:00 -0400</pubDate><dc:creator>贾斯汀·卡斯塔纳（JustineCastañeda）</dc:creator><dc:creator> Lilian Poblete</dc:creator><dc:creator> Mariana v Rosemblatt</dc:creator><dc:creator> Daniela Sauma</dc:creator><dc:creator>马里奥·罗斯姆布拉特（Mario Rosemblatt）</dc:creator><dc:creator>玛丽亚·罗莎·波诺（MaríaRosaBono）</dc:creator><dc:creator>莎拉·努涅斯（SarahNuñez）</dc:creator><dc:date> 2025-04-14</dc:date><dc:source>免疫学领域</dc:source><dc:title>胸腺居民B细胞的早期生活平衡分化为记忆B细胞</dc:title><dc:identifier>PMID：40226628</dc:identifier><dc:identifier> PMC：PMC11985456</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1567788</dc:identifier></item><item><title> MAC-1阻断阻碍粘附依赖性中性粒细胞外陷阱形成，并改善LPS诱导的败血症的肺损伤</title><link/>https://pubmed.ncbi.nlm.nih.gov/40226627/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250414161247＆v = 2.18.0.post9+e462414<description>结论：我们的发现提供了有关败血症期间净形成中EC-中性磷至直接接触的关键作用的见解，并提出MAC-1作为潜在的治疗靶点。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月28日； 16：1548913。 doi：10.3389/fimmu.2025.1548913。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：败血症是可能导致多器官损伤的常见临界条件。败血症引起的急性呼吸窘迫综合征（ARDS）通常是预后不良的重要原因，尽管存在治疗性干预措施，但与高死亡率有关。中性粒细胞浸润和细胞外陷阱（净）与急性肺损伤（ALI）和败血症后的ARD有关。作为循环中性粒细胞浸润感染的组织，它们与血管内皮细胞（EC）直接接触。尽管已经建立了网络诱导内皮损害的能力，但直接欧EC-中性嗜性相互作用在败血症过程中净形成和肺损伤中的特定作用尚不完全了解。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：在这项研究中，当中性粒细胞与ECS共培养或与之分离时，评估了净形成，并用凤凰12-溶质盐13-乙酸盐（PMA），脂多糖（LPS），脂甲酸（Lipoteichoic acta），Lipoteichoic Acid（LTA）或败血性血浆。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：我们发现，嗜中性粒细胞在EC上的粘附对于响应LP，LTA或化粪池等离子体的净形成至关重要。阻止巨噬细胞-1抗原（MAC-1）阻碍净形成，同时抑制P-选择蛋白糖蛋白配体1（PSGL-1）或白细胞功能相关的抗原1（LFA-1）。这种依赖性的净形成依赖于细胞外钙和肽基金蛋白脱节酶4（PAD4）介导的组蛋白H3的柠檬酸的流入。但是，MAC-1封锁没有改变钙的涌入。在LPS诱导的败血症的鼠模型中，MAC-1阻断减少了净释放，炎症细胞因子水平降低，缓解内皮损伤并减轻了肺损伤。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：我们的发现提供了有关败血症期间净形成中EC-中性磷至直接接触的关键作用的见解，并提出MAC-1作为潜在的治疗靶点。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40226627/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250414161247&v=2.18.0.post9+e462414">40226627</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11985419/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250414161247&v=2.18.0.post9+e462414">PMC11985419</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1548913>10.3389/fimmu.2025.1548913</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40226627</guid><pubDate> Mon, 14 Apr 2025 06:00:00 -0400</pubDate><dc:creator>金华芳</dc:creator><dc:creator>汉古丁</dc:creator><dc:creator>Jiaqi Huang</dc:creator><dc:creator>王刘</dc:creator><dc:creator>Tiantian Hong</dc:creator><dc:creator> Junxian Yang</dc:creator><dc:creator>朱韦·吴</dc:creator><dc:creator>朱李</dc:creator><dc:creator>张张</dc:creator><dc:creator>Peimin Liu</dc:creator><dc:creator> ying fang</dc:creator><dc:creator> Jianhua Wu</dc:creator><dc:creator> Xin li</dc:creator><dc:creator> Jiangguo lin</dc:creator><dc:date> 2025-04-14</dc:date><dc:source>免疫学领域</dc:source><dc:title>MAC-1阻断阻碍粘附依赖性中性粒细胞外陷阱形成，并改善LPS诱导的败血症的肺损伤</dc:title><dc:identifier>PMID：40226627</dc:identifier><dc:identifier> PMC：PMC11985419</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1548913</dc:identifier></item><item><title> MASP-1和MASP-3在视网膜变性的发展中的作用</title><link/>https://pubmed.ncbi.nlm.nih.gov/40226626/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250414161247＆v = 2.18.0.post9+e462414<description>补体通过三种不同的途径激活，即经典（CP），凝集素（LP）和替代途径（AP）。补体激活功能以消除入侵病原体，而补体激活的失调可以诱导炎症性疾病，例如与年龄相关的黄斑变性（AMD）。在由碘化钠诱导的视网膜变性中（Naio（3）），一种干燥AMD的鼠模型（也称为萎缩性AMD），已经提出AP和CP参与... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月28日； 16：1566018。 doi：10.3389/fimmu.2025.1566018。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">补体通过三种不同的途径激活，即经典（CP），凝集素（LP）和替代途径（AP）。补体激活功能以消除入侵病原体，而补体激活的失调可以诱导炎症性疾病，例如与年龄相关的黄斑变性（AMD）。在由碘化钠（Naio <sub>3</sub> ）诱导的视网膜变性中，这是一种干燥AMD的鼠模型（也称为萎缩AMD），已经提出AP和CP参与了疾病发展。另一方面，LP在AMD发展中的作用尚不清楚。在当前的研究中，我们使用缺乏甘露糖结合凝集素相关的丝氨酸蛋白酶（MASP）-1和/或MASP-3的小鼠生成了Naio <sub>3</sub>的鼠干AMD模型，分别是LP和AP激活所必需的。野生型（WT）C57BL/6J小鼠表现出视网膜变性，包括视网膜色素上皮（RPE）的脱位和破坏，光感受器层的萎缩（PL）和Naio <sub>3</sub>注射后外核层（ONL）的变薄。相反，Naio <sub>3</sub>注射后的病理变化在MASP-1缺陷型（MASP-1 <sup>- / -</sup> ），MASP-3缺陷型（MASP-3 <sup>- / -</sup> ）和MASP-1/3-Double Defication（MASP-1/3  - /3 <sup>- / -</sup> ）小鼠中显着减弱。这些结果表明，MASP-1和MASP-3都在Naio <sub>3</sub>诱导的鼠干干AMD模型的光感受器变性中起作用。另外，在NAIO <sub>3</sub>注射的WT小鼠中观察到感光细胞死亡和视网膜C3激活，而在NAIO <sub>3</sub>注射的MASP -3 <sup>- / - / -</sup>和MASP -1/3 <sup>- / -</sup>小鼠中，这些病理变化显着减弱。另一方面，NAIO <sub>3</sub>注射的MASP -1 <sup>- / -</sup>小鼠中的病理变化与NAIO <sub>3</sub>注射的WT小鼠中的病理变化相当。综上所述，我们的结果表明，MASP -3在视网膜中C3激活中起关键作用，最有可能通过激活AP激活，从而导致Naio <sub>3</sub>诱导的鼠干干AMD模型的视网膜变性发展。我们的结果还表明，在该鼠模型中，MASP -1在NAIO <sub>3</sub>诱导的视网膜变性的发展中起作用，尽管尚不清楚其在视网膜变性中的作用是否通过LP激活。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40226626/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250414161247&v=2.18.0.post9+e462414">40226626</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11985759/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250414161247&v=2.18.0.post9+e462414">PMC11985759</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1566018>10.3389/fimmu.2025.1566018</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40226626</guid><pubDate> Mon, 14 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Tomoko Omori</dc:creator><dc:creator>武田</dc:creator><dc:creator>Yumi Ishida</dc:creator><dc:creator> Tetsuju Sekiryu</dc:creator><dc:creator> hideharu sekine</dc:creator><dc:date> 2025-04-14</dc:date><dc:source>免疫学领域</dc:source><dc:title>MASP-1和MASP-3在视网膜变性的发展中的作用</dc:title><dc:identifier>PMID：40226626</dc:identifier><dc:identifier> PMC：PMC11985759</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1566018</dc:identifier></item><item><title>自身免疫性风湿性疾病患者的干扰素伽马除外 - 对COVID -19的细胞反应降低了COVID -19</title><link/> https://pubmed.ncbi.nlm.nih.gov/40226625/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250414161247＆v = 2.18.0.post9+e462414<description>全球COVID-19大流行导致疫苗研究的显着进步，特别是关于自身免疫性风湿性疾病（AIIRD）的患者。但是，大多数研究仅通过测量干扰素γ的产生来评估疫苗接种后的细胞反应。这项研究旨在探索疾病患者的疫苗接种后细胞免疫反应，重点是免疫调节药物对参与...的不同蛋白质的影响。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月28日； 16：1568439。 doi：10.3389/fimmu.2025.1568439。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">全球COVID-19大流行导致疫苗研究的显着进步，特别是关于自身免疫性风湿性疾病（AIIRD）的患者。但是，大多数研究仅通过测量干扰素γ的产生来评估疫苗接种后的细胞反应。这项研究旨在探索抗菌症患者的疫苗接种后细胞免疫反应，重点是免疫调节药物对参与细胞反应和细胞毒性涉及的不同蛋白质的影响。我们分析了来自54例患者的血液样本 -  16例健康对照（HC）和38名AiiRD患者 - 在三个时间点：（T0），（T0），（T1）后（T1）和（T2）后6个月（T2）促进疫苗后6个月以上。评估了参与细胞免疫力的13种蛋白质的基因表达和浓度水平。我们的研究表明，与HC相比，在T0时，T0和T2时T2和T2的Perforin的TNF产生显着降低。在Aiird患者中，涉及细胞毒性的基因的表达受损，包括NRF2，TRAIL，组织蛋白酶B和组织蛋白酶H。蛋白质浓度和基因表达在用糖皮质激素，甲氨蝶呤和生物/靶向合成疾病修饰的抗疾病药物（B/TSDMARDS）治疗的蛋白质表达尤其改变。在B/TSDMARD中，仅IL-17抑制剂不会影响细胞反应。这些发现表明，COVID-19疫苗接种引起的AIIRD患者，尤其是接受免疫抑制疗法的患者的细胞反应减弱，可能会损害疫苗的疗效。需要进一步的研究来确定这些发现对该人群中长期疫苗有效性的临床影响。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40226625/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250414161247&v=2.18.0.post9+e462414">40226625</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11986637/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250414161247&v=2.18.0.post9+e462414">PMC11986637</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1568439>10.3389/fimmu.2025.1568439</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40226625</guid><pubDate> Mon, 14 Apr 2025 06:00:00 -0400</pubDate><dc:creator>雅库布·沃斯基</dc:creator><dc:creator>Magdalena Massalska</dc:creator><dc:creator> BoêenaJaszczyk</dc:creator><dc:creator> Anna Felis-Giemza</dc:creator><dc:creator>安娜·科纳特卡（Anna Kornatka）</dc:creator><dc:creator> MagdalenaPlebańczyk</dc:creator><dc:creator> Tomasz Burakowski</dc:creator><dc:creator> Brygida Kwiatkowska</dc:creator><dc:creator> ewa kuca-warnawin</dc:creator><dc:creator> Marzena Ciechomska</dc:creator><dc:date> 2025-04-14</dc:date><dc:source>免疫学领域</dc:source><dc:title>自身免疫性风湿性疾病患者的干扰素伽马除外 - 对COVID -19的细胞反应降低了COVID -19</dc:title><dc:identifier> PMID：40226625</dc:identifier><dc:identifier> PMC：PMC11986637</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1568439</dc:identifier></item><item><title>败血症中的肝损伤：表现，机制和新兴治疗策略</title><link/>https://pubmed.ncbi.nlm.nih.gov/40226624/?utm_source=Chrome&amp;utm_medium = rsss＆utm_camp aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250414161247＆v = 2.18.0.post9+e462414<description>败血症被定义为与感染有关的疾病，该疾病表现出具有多器官功能障碍，代表威胁生命的状态。因此，经常发生严重的并发症，肝损伤是败血症最普遍的并发症之一。败血症期间的肝功能障碍是死亡率的独立预测指标。这篇综述概述了当前有关败血症诱发的肝损伤（SILI）的研究，包括临床表现，... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月28日； 16：1575554。 doi：10.3389/fimmu.2025.1575554。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">败血症被定义为与感染有关的疾病，该疾病表现出具有多器官功能障碍，代表威胁生命的状态。因此，经常发生严重的并发症，肝损伤是败血症最普遍的并发症之一。败血症期间的肝功能障碍是死亡率的独立预测指标。这篇综述提供了有关败血症引起的肝损伤（SILI）的当前研究的全面概述，其中包括临床表现，诊断标准，发病机理和与此疾病相关的治疗策略。硅胶可能由于缺血和休克而表现为低氧肝炎，胆汁胆代谢异常或胆管硬化症引起的胆汁淤积。败血症的病理生理涉及炎症反应，氧化应激和细胞死亡之间的复杂相互作用。所有这些因素都使治疗复杂化，并代表了治疗干预的潜在靶标。此外，这篇综述解决了当前用于管理Sili的常规疗法所固有的局限性，并强调了旨在解决这种情况下的基本机制的新型目标策略的潜力。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40226624/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250414161247&v=2.18.0.post9+e462414">40226624</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11985447/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250414161247&v=2.18.0.post9+e462414">PMC11985447</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1575554>10.3389/fimmu.2025.1575554</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40226624</guid><pubDate> Mon, 14 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Xinqi Xu</dc:creator><dc:creator> Tingyu Yang</dc:creator><dc:creator> jiapan an</dc:creator><dc:creator>本·李</dc:creator><dc:creator>Zhimin Dou</dc:creator><dc:date> 2025-04-14</dc:date><dc:source>免疫学领域</dc:source><dc:title>败血症中的肝损伤：表现，机制和新兴治疗策略</dc:title><dc:identifier>PMID：40226624</dc:identifier><dc:identifier> PMC：PMC11985447</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1575554</dc:identifier></item><item><title>外周血标志物预测IV驱动器基因阴性肺腺癌的预后和ICIS治疗</title><link/>https://pubmed.ncbi.nlm.nih.gov/40226623/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250414161247＆v = 2.18.0.post9+e462414<description>结论：对于患有ICI治疗的IV期驱动基因阴性肺腺癌的患者，PNI和转移性状态可作为PFS的初始预测指标。此外，D-二聚体水平，PNI，转移性状态和IRAES的存在最初可以预测OS，这有助于鉴定临床实践中ICI治疗的人群的鉴定。此外，我们的发现表明需要对PLR和LMR提高关注，以了解IRAES的发生。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月28日； 16：1538392。 doi：10.3389/fimmu.2025.1538392。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：本研究旨在评估外周血生物标志物在结局和与免疫相关的不良事件（IRAE）中的预后意义（IRAE）中，IV期驱动基因阴性肺腺癌接受了免疫检查点抑制剂（ICIS）的治疗。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们对102名诊断为IV期驱动基因基因 - 阴性肺腺癌的患者的临床病理数据进行了回顾性分析，他们在2019年1月1日和2023年12月31日之间在Hebei医科大学的第四次医院接受ICI治疗。我们采用了Kaplan-Meier方法。生成的生存曲线，并使用对数秩检验评估了组之间的生存差异。 COX回归模型用于PFS和OS的多元分析。此外，我们使用逻辑回归模型评估了伊拉斯外周血标记的预测值。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：分别记录了102例患者队列的1年，3年和5年PFS率，分别为35.3％，3.9％和0％；同样，观察到这些时间点的OS率为66.7％，8.8％和2.9％。多元分析表明，预后营养指数（PNI）和转移状态是影响该患者人群中PFS预后的独立预后因素；此外，D-二聚体水平，PNI，转移性状态以及IRAE的发生作为影响患者OS率的独立预后指标。随后的逻辑回归分析表明，血小板与淋巴细胞比（PLR）和淋巴细胞与单一细胞比率（LMR）起着具有统计学意义的伊拉斯的独立预测指标（P = 0.032; P = 0.02）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：对于患有ICI治疗的IV期驱动基因阴性肺腺癌的患者，PNI和转移性状态可作为PFS的初始预测指标。此外，D-二聚体水平，PNI，转移性状态和IRAES的存在最初可以预测OS，这有助于鉴定临床实践中ICI治疗的人群的鉴定。此外，我们的发现表明需要对PLR和LMR提高关注，以了解IRAES的发生。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40226623/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250414161247&v=2.18.0.post9+e462414">40226623</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11985769/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250414161247&v=2.18.0.post9+e462414">PMC11985769</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1538392>10.3389/fimmu.2025.1538392</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40226623</guid><pubDate> Mon, 14 Apr 2025 06:00:00 -0400</pubDate><dc:creator> li</dc:creator><dc:creator> Lei Cao</dc:creator><dc:creator> Lei Liu</dc:creator><dc:creator> Yawen ding</dc:creator><dc:creator>冯曹</dc:creator><dc:date>2025-04-14</dc:date><dc:source>免疫学领域</dc:source><dc:title>外周血标志物预测IV驱动器基因阴性肺腺癌的预后和ICIS治疗</dc:title><dc:identifier>PMID：40226623</dc:identifier><dc:identifier> PMC：PMC11985769</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1538392</dc:identifier></item><item><title>基于免疫疗法治疗的转移性软组织肉瘤的结果和治疗策略：一项三中心研究</title><link/>https://pubmed.ncbi.nlm.nih.gov/40226622/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250414161247＆v = 2.18.0.post9+e462414<description>结论：基于免疫疗法的治疗在生存中表现出有希望的活性，尤其是在某些组织学亚型（未分化的多态性肉瘤，去分化的脂肪肉瘤，粘粘纤维肉瘤和鼠尾草肉瘤），以及在联合治疗和早期治疗中。需要进行前瞻性研究以确认潜在的好处。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月28日； 16：1504117。 doi：10.3389/fimmu.2025.1504117。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：临床前研究表明，细胞毒性剂和抗血管生成剂对软组织肉瘤（STS）的肿瘤免疫微环境具有调节作用，然后增强免疫疗法的抗肿瘤作用。这项研究是为了研究基于免疫疗法的转移性疗法的疗效和安全性。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们在三个中心进行了回顾性分析，其中一些患者接受了基于免疫疗法的治疗，包括单独或与全身性药物（细胞毒性剂和/或抗血管生成剂）组成。主要终点是中值无进展生存期（MPF）和中位总生存期（MOS），使用Kaplan-Meier方法比较生存。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：本研究中总共包括79名患者。随着14.2个月的中位随访，MPF和MOS分别为7.5个月和19.5个月。与非ASPS组相比，肺泡软件肉瘤（ASPS）组的PFS（P &lt;0.01）和OS（P &lt;0.01）在肺泡软件肉瘤（ASP）组中明显好得多。与后续线相比，在≤2行治疗的患者的PFS（P &lt;0.01）和OS（P &lt;0.01）相比。根据组织病理学类型进行进一步的分析，在ASP的患者中，与单一疗法中的免疫疗法相比，基于免疫疗法的治疗的组合导致PFS更长（P &lt;0.01）。类似地，与后续线相比，以≤2行治疗的患者具有更长的PF（P = 0.03）和OS（P &lt;0.01）。在非ASPS患者中，与其他子类型相比，患有潜在敏感的肉瘤（未分化的多形性肉瘤，去分化的脂肪肉瘤，粘纤维果肉瘤和angiosarcoma）的患者具有更长的PFS（P = 0.02）和OS（P = 0.03）。与随后的线相比，接受潜在敏感肉瘤的患者的OS（p = 0.03）显示出长长的趋势。报告的大多数不良事件是轻度和可忍受的。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：基于免疫疗法的治疗在生存中表现出有希望的活性，尤其是在某些组织学亚型（未分化的多态性肉瘤，去分化的脂肪肉瘤，粘粘纤维肉瘤和鼠尾草肉瘤），以及在联合治疗和早期治疗中。需要进行前瞻性研究以确认潜在的好处。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40226622/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250414161247&v=2.18.0.post9+e462414">40226622</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11985850/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250414161247&v=2.18.0.post9+e462414">PMC11985850</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1504117>10.3389/fimmu.2025.1504117</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40226622</guid><pubDate> Mon, 14 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Zhiyong Liu</dc:creator><dc:creator> Yao Weitao</dc:creator><dc:creator>康库</dc:creator><dc:creator>Songtao Gao</dc:creator><dc:creator> XIN WANG</dc:creator><dc:creator>彭张</dc:creator><dc:creator>Jiaqiang Wang</dc:creator><dc:date> 2025-04-14</dc:date><dc:source>免疫学领域</dc:source><dc:title>基于免疫疗法治疗的转移性软组织肉瘤的结果和治疗策略：一项三中心研究</dc:title><dc:identifier>PMID：40226622</dc:identifier><dc:identifier> PMC：PMC11985850</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1504117</dc:identifier></item><item><title> BTLA激动剂减弱了抗类固醇哮喘的小鼠模型中Th17驱动的炎症</title><link/>https://pubmed.ncbi.nlm.nih.gov/40226621/?utm_source = chrome&amp;utm_medium = rsss＆utm_camp aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250414161247＆v = 2.18.0.post9+e462414<description>简介：耐药哮喘对皮质类固醇治疗的反应不足。驱动皮质类固醇耐药性的基本机制仍然很少理解，部分原因是没有合适的动物模型。确定驱动类固醇耐药性的免疫调节途径和机制对于开发有效的疗法至关重要。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月28日； 16：1552394。 doi：10.3389/fimmu.2025.1552394。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">简介：耐药哮喘对皮质类固醇治疗的反应不足。驱动皮质类固醇耐药性的基本机制仍然很少理解，部分原因是没有合适的动物模型。确定驱动类固醇耐药性的免疫调节途径和机制对于开发有效的疗法至关重要。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：在这项研究中，我们筛选了58种暴露于房屋尘螨的鼠菌株，并确定BXD75菌株表现出嗜中性粒细胞固定，抗类固醇的哮喘和升高的Th17细胞。进行了来自BXD75的肺CD4 <sup>+</sup> T细胞的RNA测序，以鉴定与类固醇抗性有关的免疫调节途径。评估了BTLA激动剂治疗对气道高反应性和肺部炎症的影响。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：转录组分析显示，HVEM表达增加和BTLA表达降低，分别与刺激和抑制信号相关的关键免疫调节剂。这些T细胞通过规范和非典型的NF-κB途径表现出增强的炎症信号传导。 BTLA激动剂<i>在体内的</i>治疗降低了气道的过度反应性和肺部炎症，而Th17细胞的<i>离体</i>治疗通过SHP-1诱导抑制信号，抑制了NF-κB信号传导，细胞数量降低，并降低了IL-17水平。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">讨论：我们的发现建立了BXD75小鼠作为耐药哮喘的模型，并证明BTLA激动剂会减轻气道的过度反应性和肺部炎症，从而将其作为一种潜在的治疗策略。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40226621/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250414161247&v=2.18.0.post9+e462414">40226621</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11986467/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250414161247&v=2.18.0.post9+e462414">PMC11986467</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1552394>10.3389/fimmu.2025.1552394</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40226621</guid><pubDate> Mon, 14 Apr 2025 06:00:00 -0400</pubDate><dc:creator>克里斯汀·奎奇（Christine Quach）</dc:creator><dc:creator> Xin li</dc:creator><dc:creator> PEDRAM SHAFIEI-JAHANI</dc:creator><dc:creator>梅李</dc:creator><dc:creator>史蒂芬·沉</dc:creator><dc:creator>Doumet Georges Helou</dc:creator><dc:creator>本杰明·P·赫雷尔（Benjamin P Hurrell）</dc:creator><dc:creator> Pejman Soroosh</dc:creator><dc:creator> omid akbari</dc:creator><dc:date> 2025-04-14</dc:date><dc:source>免疫学领域</dc:source><dc:title>BTLA激动剂减弱了抗类固醇哮喘的小鼠模型中Th17驱动的炎症</dc:title><dc:identifier>PMID：40226621</dc:identifier><dc:identifier> PMC：PMC11986467</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1552394</dc:identifier></item><item><title>血栓综合征与代谢综合征和炎症的关联 - 系统评价</title><link/>https://pubmed.ncbi.nlm.nih.gov/40226620/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250414161247＆v = 2.18.0.post9+e462414<description>结论：通常没有检查代谢综合征及其成分，并与PTS相关。八篇文章研究了肥胖的关联与PT的发展。这篇综述确定了肥胖，尤其是腹部或内脏肥胖与PT的发展之间的密切关联。尽管建立了PTS与VTE之间的关联，但仍需要进一步的研究来确定代谢综合征在PT发展中的作用。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月28日； 16：1519534。 doi：10.3389/fimmu.2025.1519534。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> INTRODUCTION: Post-thrombotic syndrome (PTS) is a chronic complication of deep vein thrombosis (DVT). Given its impact on vascular health, understanding risk factors for the development of PTS, as well as conditions such as metabolic syndrome that may contribute to vascular inflammation, is crucial. Metabolic syndrome is a constellation of factors that increase cardiovascular disease risk, insulin resistance, diabetes mellitus (DM), and cerebrovascular disease. Despite the established connection between metabolic syndrome and venous thromboembolism (VTE), the association between metabolic syndrome and PTS has yet to be explored. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: A literature search identified studies regarding PTS and metabolic syndrome and the individual components of metabolic syndrome. A specialist performed the search, and studies were identified through PubMed, Ovid Medline, and Cochrane in accordance with PRISMA guidelines. Search terms included &quot;post-thrombotic syndrome&quot; and &quot;metabolic syndrome&quot; as well as &quot;obesity,&quot; &quot;hyperglycemia,&quot; &quot;hypertension,&quot; &quot;dyslipidemia,&quot; and &quot;insulin resistance.&quot; Two people independently screened articles and consolidated differences. Abstract-only studies, review articles, case studies, and conference abstracts were excluded. Case reports, literature reviews, and studies not discussing PTS were excluded. Prospective cohort, retrospective cohort, and case-control studies were included. All English-based studies that met inclusion criteria published before January 3rd, 2024, were included. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: 281 articles were initially identified. After abstract and title screening, 16 articles underwent full-text review. Of the 16 articles that underwent review, nine were included in the final analysis. Among the selected articles, eight out of nine mentioned obesity as a risk factor for developing PTS, making it the most common component mentioned. Hypertension, diabetes mellitus, hyperlipidemia, and low high-density lipoprotein (HDL) followed in prevalence. There was no noted difference between inflammatory markers in patients with and without PTS. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSION: Metabolic syndrome and its components, individually and in association with PTS, are not commonly examined. Eight articles examined the association of obesity with the development of PTS. This review identified a strong association between obesity, particularly abdominal or visceral obesity, and the development of PTS. While the association between PTS and VTE is established, further research is needed to identify the role of metabolic syndrome in the development of PTS.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40226620/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250414161247&v=2.18.0.post9+e462414">40226620</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11985455/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250414161247&v=2.18.0.post9+e462414">PMC11985455</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2025.1519534>10.3389/fimmu.2025.1519534</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:40226620</guid><pubDate> Mon, 14 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Sara Alturky</dc:creator><dc:creator> Yusuf Ashfaq</dc:creator><dc:creator> Ajit Elhance</dc:creator><dc:creator> Megan Barney</dc:creator><dc:creator> Ishaq Wadiwala</dc:creator><dc:creator> Anna K Hunter</dc:creator><dc:creator> Khanh P Nguyen</dc:creator><dc:date> 2025-04-14</dc:date><dc:source>免疫学领域</dc:source><dc:title>Association of post-thrombotic syndrome with metabolic syndrome and inflammation - a systematic review</dc:title><dc:identifier> pmid:40226620</dc:identifier><dc:identifier> pmc:PMC11985455</dc:identifier><dc:identifier> doi:10.3389/fimmu.2025.1519534</dc:identifier></item><item><title> Evaluation of cerebrospinal fluid treponema pallidum particle agglutination assay titer for neurosyphilis diagnosis among HIV-negative syphilis patients</title><link/> https://pubmed.ncbi.nlm.nih.gov/40226619/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250414161247&amp;v=2.18.0.post9+e462414<description> CONCLUSION: This study revealed that a CSF-TPPA titer ≥ 1:320 can be used as a highly sensitive and practical marker for diagnosing neurosyphilis. A titer threshold of ≥1:320 could offer a reliable alternative in cases when CSF-VDRL is negative. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Front Immunol</b> . 2025 Mar 28;16:1572137. doi: 10.3389/fimmu.2025.1572137. eCollection 2025.</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> PURPOSE: The study aimed to assess the association between CSF-TPPA titer and the presence of neurosyphilis, and to determine the optimal CSF-TPPA titer cutoff for diagnosing neurosyphilis. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: We conducted a cross-sectional study at a single center from April 2020 and January 2022.Receiver operating characteristic (ROC) analysis was used to assess the performance of CSF-TPPA titer in the diagnosis for neurosyphilis. The relationship between CSF-TPPA titer and neurosyphilis was investigated by restricted cubic spline (RCS) curves. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: A total of 715 HIV-negative syphilis patients were included in the final analysis. CSF-TPPA was reactive in 443 cases (62.0%), with a median titer of 1:160 (IQR, Negative to 1:2560). The area under curve (AUC) of CSF-TPPA titer was 0.967 (95% Confidence interval (CI): 0.951- 0.979). CSF-TPPA titer ≥ 1:320 provided a sensitivity of 92.53% and a specificity of 87.96% for the identification of neurosyphilis. For those presumptive neurosyphilis patients, CSF-TPPA ≥1:320 could effectively identified symptomatic neurosyphilis. The RCS curve revealed a non-linear and positive association between CSF-TPPA titer and risk of neurosyphilis. After full adjustments for confounding covariates, it showed that the prevalence of neurosyphilis was relatively flat until CSF-TPPA titer reached 1:320 and then started to escalated rapidly afterwards. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSION: This study revealed that a CSF-TPPA titer ≥ 1:320 can be used as a highly sensitive and practical marker for diagnosing neurosyphilis. A titer threshold of ≥1:320 could offer a reliable alternative in cases when CSF-VDRL is negative.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40226619/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250414161247&v=2.18.0.post9+e462414">40226619</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11985789/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250414161247&v=2.18.0.post9+e462414">PMC11985789</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2025.1572137>10.3389/fimmu.2025.1572137</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:40226619</guid><pubDate> Mon, 14 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Mei Shi</dc:creator><dc:creator> Fuquan Long</dc:creator><dc:creator> Danyang Zou</dc:creator><dc:creator> Xin Gu</dc:creator><dc:creator> Liyan Ni</dc:creator><dc:creator> Yuanyuan Cheng</dc:creator><dc:creator> Tengfei Qi</dc:creator><dc:creator> Wei Zhao</dc:creator><dc:creator> Lin Zhu</dc:creator><dc:creator> Zhifang Guan</dc:creator><dc:creator> Pingyu Zhou</dc:creator><dc:date> 2025-04-14</dc:date><dc:source>免疫学领域</dc:source><dc:title>Evaluation of cerebrospinal fluid treponema pallidum particle agglutination assay titer for neurosyphilis diagnosis among HIV-negative syphilis patients</dc:title><dc:identifier> pmid:40226619</dc:identifier><dc:identifier> pmc:PMC11985789</dc:identifier><dc:identifier> doi:10.3389/fimmu.2025.1572137</dc:identifier></item><item><title> The role of macrophages in hypertrophic scarring: molecular to therapeutic insights</title><link/> https://pubmed.ncbi.nlm.nih.gov/40226618/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250414161247&amp;v=2.18.0.post9+e462414<description> Hypertrophic Scar (HS) is a common fibrotic disease of the skin, usually caused by injury to the deep dermis due to trauma, burns, or surgical injury. The main feature of HS is the thickening and hardening of the skin, often accompanied by itching and pain, which seriously affects the patient&#39;s quality of life. Macrophages are involved in all stages of HS genesis through phenotypic changes. M1-type macrophages primarily function in the early inflammatory phase by secreting pro-inflammatory... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Front Immunol</b> . 2025 Mar 28;16:1503985. doi: 10.3389/fimmu.2025.1503985. eCollection 2025.</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Hypertrophic Scar (HS) is a common fibrotic disease of the skin, usually caused by injury to the deep dermis due to trauma, burns, or surgical injury. The main feature of HS is the thickening and hardening of the skin, often accompanied by itching and pain, which seriously affects the patient&#39;s quality of life. Macrophages are involved in all stages of HS genesis through phenotypic changes. M1-type macrophages primarily function in the early inflammatory phase by secreting pro-inflammatory factors, while M2-type macrophages actively contribute to tissue repair and fibrosis. Despite advances in understanding HS pathogenesis, the precise mechanisms linking macrophage phenotypic changes to fibrosis remain incompletely elucidated. This review addresses these gaps by discussing the pathological mechanisms of HS formation, the phenotypic changes of macrophages at different stages of HS formation, and the pathways through which macrophages influence HS progression. Furthermore, emerging technologies for HS treatment and novel therapeutic strategies targeting macrophages are highlighted, offering potential avenues for improved prevention and treatment of HS.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40226618/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250414161247&v=2.18.0.post9+e462414">40226618</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11986478/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250414161247&v=2.18.0.post9+e462414">PMC11986478</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2025.1503985>10.3389/fimmu.2025.1503985</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:40226618</guid><pubDate> Mon, 14 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Lele Shen</dc:creator><dc:creator> Yao Zhou</dc:creator><dc:creator> Jie Gong</dc:creator><dc:creator> Hongqiao Fan</dc:creator><dc:creator> Lifang Liu</dc:creator><dc:date> 2025-04-14</dc:date><dc:source>免疫学领域</dc:source><dc:title>The role of macrophages in hypertrophic scarring: molecular to therapeutic insights</dc:title><dc:identifier> pmid:40226618</dc:identifier><dc:identifier> pmc:PMC11986478</dc:identifier><dc:identifier> doi:10.3389/fimmu.2025.1503985</dc:identifier></item><item><title> Identification of a novel prognostic marker ADGRG6 in pancreatic adenocarcinoma: multi-omics analysis and experimental validation</title><link/> https://pubmed.ncbi.nlm.nih.gov/40226617/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250414161247&amp;v=2.18.0.post9+e462414<description> CONCLUSIONS: ADGRG6 may serve as a novel prognostic marker and a therapeutic targets for PAAD, playing a crucial role in the proliferation, metastasis, and immune marker regulation of PAAD through elevating protein level of mutated p53. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Front Immunol</b> . 2025 Mar 27;16:1530789. doi: 10.3389/fimmu.2025.1530789. eCollection 2025.</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Pancreatic adenocarcinoma (PAAD) ranks among the most lethal malignancies worldwide. Current treatment options have limited efficacy, underscoring the need for new therapeutic targets. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: This study employed a multi-omics analytical framework to delve into the expression profiles and prognostic implications of ADGRG6 within the pan-cancer dataset of The Cancer Genome Atlas (TCGA) database, highlighting the prognostic value and potential carcinogenic role of ADGRG6 in PAAD, which was further validated using data from multiple PAAD cohorts in the Gene Expression Omnibus (GEO) 数据库。 To assess the role of ADGRG6 in the tumor microenvironment of PAAD, we evaluated immune infiltration using CIBERSORT, ssGSEA, xCell and Tracking Tumor Immunophenotype (TIP), and utilized single-cell sequencing data to explore cell-cell interactions. Further cellular and animal experiments, such as colony formation assay, transwell assay, western blot, real-time PCR, and tumor xenograft experiments, were used to investigate the effect of ADGRG6 on the proliferation, metastatic potential and immune marker expression of PAAD and the underlying mechanisms. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: ADGRG6 emerged as a potential prognostic biomarker and a therapeutic target for PAAD, which was further corroborated by data extracted from multiple PAAD cohorts archived in the GEO database. Single-cell sequencing and immune infiltration analyses predicted the positive correlation of ADGRG6 with the infiltration of immune cells and with the interaction between malignant cells and fibroblasts/macrophages within the PAAD microenvironment. <i>In vitro</i> cell assays demonstrated that ADGRG6 promoted the proliferation, metastatic potential and immune marker expression of PAAD cells by increasing protein level of mutated p53 (mutp53), which activated a spectrum of gain-of-functions to promote cancer progression via the EGFR, AMPK and NF-κB signaling cascades. Furthermore, subcutaneous xenograft experiments in mice demonstrated that ADGRG6 knockdown substantially suppressed the growth of engrafted PAAD tumors. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: ADGRG6 may serve as a novel prognostic marker and a therapeutic targets for PAAD, playing a crucial role in the proliferation, metastasis, and immune marker regulation of PAAD through elevating protein level of mutated p53.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40226617/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250414161247&v=2.18.0.post9+e462414">40226617</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11986822/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250414161247&v=2.18.0.post9+e462414">PMC11986822</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2025.1530789>10.3389/fimmu.2025.1530789</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:40226617</guid><pubDate> Mon, 14 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Han Wu</dc:creator><dc:creator> Jin Shang</dc:creator><dc:creator> Yuanyan Bao</dc:creator><dc:creator> Huajie Liu</dc:creator><dc:creator> Haoran Zhang</dc:creator><dc:creator> Yaosheng Xiao</dc:creator><dc:creator> Yangtaobo Li</dc:creator><dc:creator> Zhaozhang Huang</dc:creator><dc:creator> Xiaolei Cheng</dc:creator><dc:creator> Zixuan Ma</dc:creator><dc:creator> Wenqing Zhang</dc:creator><dc:creator> Pingli Mo</dc:creator><dc:creator> Daxuan Wang</dc:creator><dc:creator> Mingqing Zhang</dc:creator><dc:creator> Yanyan Zhan</dc:creator><dc:date> 2025-04-14</dc:date><dc:source>免疫学领域</dc:source><dc:title>Identification of a novel prognostic marker ADGRG6 in pancreatic adenocarcinoma: multi-omics analysis and experimental validation</dc:title><dc:identifier> pmid:40226617</dc:identifier><dc:identifier> pmc:PMC11986822</dc:identifier><dc:identifier> doi:10.3389/fimmu.2025.1530789</dc:identifier></item><item><title> γδT cells, a key subset of T cell for cancer immunotherapy</title><link/> https://pubmed.ncbi.nlm.nih.gov/40226616/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250414161247&amp;v=2.18.0.post9+e462414<description> γδT cells represent a unique and versatile subset of T cells characterized by the expression of T-cell receptors (TCRs) composed of γ and δ chains. Unlike conventional αβT cells, γδT cells do not require major histocompatibility complex (MHC)-dependent antigen presentation for activation, enabling them to recognize and respond to a wide array of antigens, including phosphoantigens, stress-induced ligands, and tumor-associated antigens. While γδT cells are relatively rare in peripheral blood,... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Front Immunol</b> . 2025 Mar 28;16:1562188. doi: 10.3389/fimmu.2025.1562188. eCollection 2025.</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> γδT cells represent a unique and versatile subset of T cells characterized by the expression of T-cell receptors (TCRs) composed of γ and δ chains. Unlike conventional αβT cells, γδT cells do not require major histocompatibility complex (MHC)-dependent antigen presentation for activation, enabling them to recognize and respond to a wide array of antigens, including phosphoantigens, stress-induced ligands, and tumor-associated antigens. While γδT cells are relatively rare in peripheral blood, they are enriched in peripheral tissues such as the skin, intestine, and lung. These cells play a crucial role in tumor immunotherapy by exerting direct cytotoxicity through the production of inflammatory cytokines (eg, interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α), and interleukin-17 (IL-17)) and cytotoxic molecules (eg, perforin and granzyme). Recent advances in γδT cell research have elucidated their mechanisms of tumor recognition, including the detection of phosphoantigens and stress-induced ligands like MICA (MHC class I polypeptide-related sequence A), MICB (MHC class I polypeptide-related sequence B), and ULBP (UL16-binding protein). Furthermore, various strategies to enhance γδT cell-based tumor immunotherapy have been developed, such as <i>in vitro</i> expansion using phosphoantigen-based therapies, cytokine stimulation, and chimeric antigen receptor (CAR)-γδT cell engineering. These advancements have shown promising results in both preclinical and clinical settings, paving the way for γδT cells to become a powerful tool in cancer immunotherapy. This review highlights the key mechanisms, functions, and strategies to harness the potential of γδT cells for effective tumor immunotherapy.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40226616/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250414161247&v=2.18.0.post9+e462414">40226616</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11985848/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250414161247&v=2.18.0.post9+e462414">PMC11985848</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2025.1562188>10.3389/fimmu.2025.1562188</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:40226616</guid><pubDate> Mon, 14 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Jianzhen Lv</dc:creator><dc:creator> Zheng Liu</dc:creator><dc:creator> Xiangting Ren</dc:creator><dc:creator> Siyuan Song</dc:creator><dc:creator> Yan Zhang</dc:creator><dc:creator> Yi Wang</dc:creator><dc:date> 2025-04-14</dc:date><dc:source>免疫学领域</dc:source><dc:title>γδT cells, a key subset of T cell for cancer immunotherapy</dc:title><dc:identifier> pmid:40226616</dc:identifier><dc:identifier> pmc:PMC11985848</dc:identifier><dc:identifier> doi:10.3389/fimmu.2025.1562188</dc:identifier></item></channel></rss>